Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J de Seze

Showing results (11-20 of 174) with videos related to

Pageof 18
Sort By:
Revue Neurologique|April 9, 2020
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? YesJ de Seze, K Bigaut
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2005
Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phaseJ de Seze, P Vermersch
Revue Neurologique|April 19, 2020
Covid-19, the pandemic war: Implication for neurologistsJ de Seze, C Lebrun-Frenay
Revue Neurologique|November 7, 2017
Multiple sclerosis treatments and the anti-JCV antibody indexJ de Seze, C Lebrun-Frenay
La Revue De Medecine Interne|May 5, 2005
[Neurological manifestations in Sjögren syndrome]J de Seze, S Delalande, P Vermersch
Revue Neurologique|April 2, 2002
[Sensory disorders in multiple sclerosis (before optic neuropathy)]R Assouad, J de Seze, P Vermersch
Revue Neurologique|June 15, 1999
[Tibial muscular dystrophy. A rare form of distal myopathy]J de Seze, B Udd, P Vermersch
Lupus|April 5, 2005
Mycophenolate mofetil and neurological diseasesP Vermersch, T Stojkovic, J de Seze
Acta Neurologica Belgica|February 11, 2011
Cerebrovascular symptomatic involvement in sarcoidosisA Degardin, P Devos, P Vermersch, et al.
Revue Neurologique|May 15, 2010
[Love and neurology]N Collongues, B Cretin, J de Seze, et al.
Pageof 18

Showing results (11-20 of 174) with videos related to

Sort By:
Pageof 18
Revue Neurologique|April 9, 2020
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? YesJ de Seze, K Bigaut
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2005
Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phaseJ de Seze, P Vermersch
Revue Neurologique|April 19, 2020
Covid-19, the pandemic war: Implication for neurologistsJ de Seze, C Lebrun-Frenay
Revue Neurologique|November 7, 2017
Multiple sclerosis treatments and the anti-JCV antibody indexJ de Seze, C Lebrun-Frenay
La Revue De Medecine Interne|May 5, 2005
[Neurological manifestations in Sjögren syndrome]J de Seze, S Delalande, P Vermersch
Revue Neurologique|April 2, 2002
[Sensory disorders in multiple sclerosis (before optic neuropathy)]R Assouad, J de Seze, P Vermersch
Revue Neurologique|June 15, 1999
[Tibial muscular dystrophy. A rare form of distal myopathy]J de Seze, B Udd, P Vermersch
Lupus|April 5, 2005
Mycophenolate mofetil and neurological diseasesP Vermersch, T Stojkovic, J de Seze
Acta Neurologica Belgica|February 11, 2011
Cerebrovascular symptomatic involvement in sarcoidosisA Degardin, P Devos, P Vermersch, et al.
Revue Neurologique|May 15, 2010
[Love and neurology]N Collongues, B Cretin, J de Seze, et al.
Pageof 18